
“The best payload is an immune cell” @HHammersMD ENPP3 T Cell Engager data from @montypal @KotechaMD Prostate oncologists might argue it’s a radioligand, but perhaps he is correct in RCC. #UromigosLive #uromigos @Uromigos @OncoAlert
✓Medical oncologist with focus on kidney cancer, immunotherapies and the tumor microenvironment. Views expressed are my own. #kidneycancer #immunotherapy

“The best payload is an immune cell” @HHammersMD ENPP3 T Cell Engager data from @montypal @KotechaMD Prostate oncologists might argue it’s a radioligand, but perhaps he is correct in RCC. #UromigosLive #uromigos @Uromigos @OncoAlert


This is a game changer!! 45% durable ORRs at higher dose levels. READY for prime time and will change early treatment lines. As excited as when I first saw PD1 results in RCC. This will transform front lines and cure more patients.

ENPP3 x CD3 ! Seismic Shift to come !! Let’s end using non IO drugs in the frontline and focus on CURE!

Well well well… This was certainly my favorite RCC / kidney cancer presentation and heralding a significant shift in the RCC landscape! 45% response in heavily pretreated pts. Highly impressive! Needs to move into frontline combinations! Congrats @montypal + colleagues




Our melanoma team recently treated its first patient with advanced melanoma using tumor-infiltrating lymphocyte (TIL) therapy. Congratulations to the entire team on this important achievement! Learn more about TIL therapy: bit.ly/3UDhnvu.

Congratulations to Dr. Yousef Zakharia of Mayo Clinic, recipient of the 2026 Outstanding Advocacy Leadership Award. This award recognizes individuals whose leadership and dedication to advocacy have helped advance kidney cancer research and improve the lives of patients. Through his commitment to collaboration and advocacy, Dr. Zakharia has been an important voice for continued progress in the kidney cancer community. Congratulations on this well-deserved honor, and thank you for your continued leadership. #KCRS26 #AcceleratingCures

Congratulations to the 2026 AACR–KidneyCAN Innovation & Discovery Grant recipients! This year's awardees are: • Jessica Spinelli, PhD, University of Massachusetts Chan Medical School • Maralice Conacci-Sorrell, PhD, UT Southwestern Medical Center • Ritesh Kotecha, MD, Memorial Sloan Kettering Cancer Center These grants support innovative, high-impact research with the potential to transform our understanding of kidney cancer and accelerate the development of new treatments. Congratulations to this exceptional group of investigators on this well-deserved recognition! #KCRS26 #AcceleratingCures

Register now for our 2026 Oncology Year in Review CME! bit.ly/4wVJHHR This program will provide participants with the latest information available, as presented at the @ASCO meeting, @myESMO meeting, and other meetings that took place in 2026, from our experts.

Clinical trials have helped keep me alive for more than a decade. I know firsthand that finding the right trial at the right time can change everything. That’s why I’m excited about @KidneyCAN’s new Clinical Trial Navigator, helping kidney cancer patients more easily find trials that could provide their next option. Patients shouldn’t have to become experts at searching for clinical trials while fighting cancer. We need to make it easier to find the science, understand the options and know what to do next. For some of us, a clinical trial isn’t just research. It’s hope. It’s another option. It’s more time. kidneycancertrials.org Thank you @kidneycan for launching a tool that helps all kidney cancer patients. #ClinicalTrials

What an incredible two days. #KCRS26 brought together researchers, clinicians, industry leaders, advocates, and patient representatives from around the world to share discoveries, challenge ideas, build collaborations, and inspire the next generation of #KidneyCancer research. From groundbreaking keynote presentations and innovative abstract sessions to Rock the Run, Posters & Prosecco, and countless conversations in the hallways, every moment reflected the passion and dedication of this remarkable community. Thank you to everyone who joined us, whether in Boston or virtually. Together, we're accelerating progress toward better treatments and brighter futures for people affected by kidney cancer. We'll see you next year. #AcceleratingCures

Volumetric is the Key! Just the longest diameter may mean nothing, deflating a “balloon” may do little to the longest diameter but yet you may have reduced tumor burden by 90+% and might be cured!

The true legacy of mentorship is not one successful investigator, but generations of them. @DrChoueiri impact on the global RCC community is extraordinary. #AcceleratingCures #KCRS26 @kidneycan @DrChoueiri @HHammersMD @IKCCorg @advocatekidneys @DrRanaMcKay @NazliDizman @MikeSerzanMD @crisbergerot @Uromigos @OncoAlert @OpenMedicineHQ @montypal @arihakimi @TiansterZhang @AlbigesL @ReneeSaliby @VincentWenxinXu @yekeduz_emre @g_develasco @FabioSchutz78 @lalaniMD @Dominick_Bosse @DrRanaMcKay @maxinesun @BraunMDPhD